Is CDK12 deficiency a clinically relevant predictive biomarker of PARP1/2 inhibitor sensitivity?
The state of play in overcoming resistance to RAF inhibition in metastatic melanoma - where do we go next?
Dr Carol Gallagher is the former CEO of Calistoga before it was acquired by Gilead. CAL-101, a PI3K-delta inhibitor is now known as idelalisib and in phase 3 development for CLL and indolent NHL.
This is a great example of a successful R&D strategy for a targeted therapy that is making a difference to patients lives.